Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. (Q43249154)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Enrico Derenzini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Lisa Argnani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

F Venturini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

V Stefoni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M Fina

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

C Pellegrini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

L Gandolfi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Broccoli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

F Quirini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Pileri

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M Baccarani

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

3 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

860-863

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Treatment of T-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggre

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

TNM classification of malignant tumors. A comparison between the new (1987) and the old editions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP508

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP508

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887465%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference